Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

110.83 -0.70 (-0.63%)
Streaming Delayed Price Updated: 12:29 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
55 56 Next >
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
From Gilead Sciences, Inc.
Via Business Wire
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
Regulators are already on the case, and their findings will have financial impacts. 
Via The Motley Fool
3 biotech powerhouses poised to thrive amid sector rebound
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader. 
Via MarketBeat
Topics ETFs
A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene
Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
A Look Into Gilead Sciences Inc's Price Over Earnings
Via Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $11,000 Today
Via Benzinga
Looking Into Gilead Sciences's Recent Short Interest
Via Benzinga
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases. 
Via InvestorPlace
3 Biotech Stocks That Could Be Multibaggers in the Making
Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments. 
Via InvestorPlace
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
From Gilead Sciences, Inc.
Via Business Wire
2 Biotech Stocks You Can Buy and Hold for the Next Decade
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off. 
Via The Motley Fool
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
Tuesday, the FDA said it received reports of patients developing T-cell malig 
Via Benzinga
Exposures Product Safety
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today
Via Benzinga
Is NASDAQ:GILD suited for dividend investing?
Why the dividend investor may take a look at GILEAD SCIENCES INC (NASDAQ:GILD). 
Via Chartmill
Gilead Sciences's Options: A Look at What the Big Money is Thinking
Via Benzinga
J&J, Gilead, BMS: A look at undervalued dividend payers
J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown 
Via MarketBeat
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
There's no time like the present to buy these stocks. 
Via The Motley Fool
Stocks Stall On November 21, 2023, As Systematic Flows Abate
Stocks finished the day lower by roughly 20 bps, which is not a big deal, as rates fell somewhat and the dollar rallied 
Via Talk Markets
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug
FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative... 
Via Benzinga
Exposures Product Safety
In a market where value is scarce, NASDAQ:GILD offers a refreshing opportunity with its solid fundamentals.
GILEAD SCIENCES INC (NASDAQ:GILD): good value for what you're paying. 
Via Chartmill
A Closer Look at Gilead Sciences's Options Market Dynamics
Via Benzinga
Where Gilead Sciences Stands With Analysts
Via Benzinga
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead
The companies will work together on treatments for multiple myeloma and lymphomas. 
Via Investor's Business Daily
Kite and Arcellx Announce Expansion in Strategic Partnership
From Gilead Sciences, Inc.
Via Business Wire
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
The major indexes ended long win streaks. Datadog led earnings winners. 
Via Investor's Business Daily
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:BMY),(NASDAQ:GILD),(NYSE:MRK),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Buying the dip in high-yield Gilead Sciences
Pharma stock Gilead Sciences is well-positioned for the next few years with a growing core business, a healthy pipeline, and cash flow to sustain capital return 
Via MarketBeat
Exposures COVID-19
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Tops Q3 Earnings And Revenue Estimates
While Gilead has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? 
Via Talk Markets
Gilead Sciences (GILD) Q3 2023 Earnings Call Transcript
GILD earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
55 56 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.